Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Trevi Therapeutics, Inc. (TRVI) had Consolidated Net Income/Loss of $-42.76M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-42.76M |
|
-- |
|
-- |
|
$49.33M |
|
$-49.33M |
|
$6.50M |
|
$-42.82M |
|
$-42.82M |
|
$-42.76M |
|
$-42.76M |
|
|
Consolidated Net Income/Loss |
$-42.76M |
$-42.76M |
|
$-49.33M |
|
$-49.18M |
|
134.75M |
|
134.75M |
|
$-0.32 |
|
$-0.32 |
|
| Balance Sheet Financials | |
$191.66M |
|
$0.18M |
|
$1.78M |
|
$193.44M |
|
$9.75M |
|
-- |
|
$0.45M |
|
$10.20M |
|
$183.24M |
|
$183.24M |
|
$183.24M |
|
128.31M |
|
| Cash Flow Statement Financials | |
$-42.09M |
|
$-94.11M |
|
$121.01M |
|
$34.10M |
|
$18.91M |
|
$-15.18M |
|
$5.18M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
19.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-42.10M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-23.33% |
|
-23.33% |
|
-22.10% |
|
-23.33% |
|
$1.43 |
|
$-0.31 |
|
$-0.31 |
|